| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 02/14/2007 | EP1751120A2 Substituted triazoles as modulators of ppar and methods of their preparation |
| 02/14/2007 | EP1751119A1 Novel fused heterocycles and uses thereof |
| 02/14/2007 | EP1751118A1 Pyrimidines for use as plk inhibitors |
| 02/14/2007 | EP1751116A2 Pyrimidine compounds and use thereof |
| 02/14/2007 | EP1751113A1 Urea antagonists of p2y1 receptor useful in the treatment of thrombotic conditions |
| 02/14/2007 | EP1751111A1 Substituted 1,2,3,4-tetrahydroisoquinoline derivatives |
| 02/14/2007 | EP1751108A1 Adamantyl-acetamide derivatives as inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme |
| 02/14/2007 | EP1751106A1 Piperazine derivatives of alkyl oxindoles |
| 02/14/2007 | EP1751105A1 Piperazine derivatives of alkyl oxindoles |
| 02/14/2007 | EP1751103A1 4-(5-(aminomethyl)-indole-1-ylmethyl)-benzamide derivatives and related compounds as opioid receptor antagonists for the treatment of obesity |
| 02/14/2007 | EP1751102A1 Process for producing a dipeptidyl peptidase iv inhibitor |
| 02/14/2007 | EP1751101A1 Substituted 5-aminomethyl-1h-pyrrol-2-carbxylic acid amides |
| 02/14/2007 | EP1751100A1 Anti-tubulin acting arylpyrrol, arylfulran and arylthiopene derivatives, method for the preparation and use thereof as an antimitotic |
| 02/14/2007 | EP1751099A1 Cis pyrrolidinyl derivatives and their uses |
| 02/14/2007 | EP1751098A1 Trans pyrrolidinyl derivatives and their pharmaceutical use |
| 02/14/2007 | EP1751097A1 Substituted n-aryl benzamides and related compounds for treatment of amyloid diseases and synucleinopathies |
| 02/14/2007 | EP1751096A2 Salt of 4- or 5- aminosalicylic acid |
| 02/14/2007 | EP1751094A2 Beta-peptides |
| 02/14/2007 | EP1751093A1 Substituted cyclohexylacetic acid derivatives |
| 02/14/2007 | EP1751091A2 2-amino- and 2-thio-substituted 1,3-diaminopropanes |
| 02/14/2007 | EP1751089A2 Novel m3 muscarinic acetylcholine receptor antagonists |
| 02/14/2007 | EP1751087A1 Levodopa prodrugs, and compositions and uses thereof |
| 02/14/2007 | EP1751086A2 DIAMINE ß2 ADRENERGIC RECEPTOR AGONISTS |
| 02/14/2007 | EP1751085A1 Stable atomoxetine hydrochloride, a process for the preparation thereof, and an analytical control of its stability |
| 02/14/2007 | EP1750862A2 Pharmaceutical composition containing irbesartan |
| 02/14/2007 | EP1750808A2 Myricitrin compounds for treating sleeping disorders |
| 02/14/2007 | EP1750807A2 Glycopyrrolate for treating childhood asthma |
| 02/14/2007 | EP1750806A2 Treating respiratory diseases with glycopyrrolate and analogues |
| 02/14/2007 | EP1750805A2 Pyrroloquinoline quinone drugs for treatment of cardiac injury |
| 02/14/2007 | EP1750783A2 Hyaluronic acid based copolymers |
| 02/14/2007 | EP1750776A2 Oligonucleotides comprising a c5-modified pyrimidine |
| 02/14/2007 | EP1750772A1 Phospholipase c gamma modulation and uses thereof for management of pain and nociception |
| 02/14/2007 | EP1750770A1 Use of organo-silicon compounds for constraining connective damaged tissues |
| 02/14/2007 | EP1750768A2 Use of targeted oxidative therapeutic formulation in bone regeneration |
| 02/14/2007 | EP1750766A2 Pharmaceutical formulations and uses thereof in the treatment of female sexual dysfunction |
| 02/14/2007 | EP1750765A2 Antimycobacterial pharmaceutical composition comprising an antitubercular drug |
| 02/14/2007 | EP1750756A2 Compositions and methods for enhanced mucosal delivery of parathyroid hormone |
| 02/14/2007 | EP1750744A1 Medicament for the treatment of fungal infections, particularly aspergillosis |
| 02/14/2007 | EP1750730A2 Treatment of hypercholesterolemia, hypertriglyceridemia and cardiovascular-related conditions using phosphalipase-a2 inhibitors |
| 02/14/2007 | EP1750729A2 Solid dosage form of wetted heparin |
| 02/14/2007 | EP1750728A1 Prevention of arterial restenosis with active vitamin d compounds |
| 02/14/2007 | EP1750727A2 Kinase modulators and methods of use |
| 02/14/2007 | EP1750726A2 Spermicidal and virucidal properties of various forms of sophorolipids |
| 02/14/2007 | EP1750725A1 Compositions comprising mannose phosphate for vaginal treatment |
| 02/14/2007 | EP1750724A1 Method for improving cognitive function by co-administration of a gabab receptor antagonist and an acetylcholinesterase inhibitor |
| 02/14/2007 | EP1750723A1 Carotenoid analogs or derivatives for the inhibition and amelioration of inflammation |
| 02/14/2007 | EP1750722A2 Novel lysophosphatidic acid receptor selective antagonists |
| 02/14/2007 | EP1750721A1 Topical cromolyn formulations |
| 02/14/2007 | EP1750720A2 Hepoxilins and modulators of ichthyin for treating skin disorders |
| 02/14/2007 | EP1750719A2 Treatment of diseases associated with altered level of amyloid beta peptides |
| 02/14/2007 | EP1750718A1 Acyclovir formulations |
| 02/14/2007 | EP1750717A2 Controlled release pharmaceutical compositions with improved bioavailability |
| 02/14/2007 | EP1750716A1 Treatment of t-cell lymphoma using 10-propargyl-10-deazaaminopterin |
| 02/14/2007 | EP1750715A1 Methods for treating mast cell disorders |
| 02/14/2007 | EP1750714A1 Phosphoinositide 3-kinase delta selective inhibitors for inhibiting angiogenesis |
| 02/14/2007 | EP1750713A1 Use of imatinib to treat liver disorders and viral infections |
| 02/14/2007 | EP1750712A2 Medicaments containing n-sulfamoyl-n'-arylpiperazines for the prophylaxis or treatment of obesity and related conditions |
| 02/14/2007 | EP1750711A2 Treatment of neurogenerative and inflammatory conditions with morphinan |
| 02/14/2007 | EP1750710A1 Neuroprotective properties of dextrorotatory morphinans |
| 02/14/2007 | EP1750709A2 Method for the treatment of back pain |
| 02/14/2007 | EP1750708A1 Combinations of substituted 1-phenyl-1,5-dihydro-pyrido- [3,2-b] indol-2-ones and other hiv inhibitors |
| 02/14/2007 | EP1750707A1 Immunostimulant composition comprising at least one toll-like receptor 7 or toll-like receptor 8 agonist and toll-like receptor 4 agonist |
| 02/14/2007 | EP1750706A1 Dual small molecule inhibitors of cancer and angiogenesis |
| 02/14/2007 | EP1750705A1 Selective serotonin receptor inverse agonists as therapeutics for disease |
| 02/14/2007 | EP1750704A2 Urea antagonists of p2y1 receptor useful in the treatment of thrombotic conditions |
| 02/14/2007 | EP1750703A1 Method for reducing gastrointestinal toxicity due to the administration of tegafur |
| 02/14/2007 | EP1750702A1 Method of bowel cleansing |
| 02/14/2007 | EP1750701A1 Amorphous clopidogrel hydrochloride and its antithrombotic use |
| 02/14/2007 | EP1750700A1 Liquid preparation for veterinary medicine, method for the production thereof, and use of the same |
| 02/14/2007 | EP1750699A2 Treatment of diet-related conditions using phospholipase-a2 inhibitors comprising indoles and related compounds |
| 02/14/2007 | EP1750698A2 5-anilino-4-heteroarylpyrazole derivatives useful for the treatment of diabetes |
| 02/14/2007 | EP1750697A1 Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases |
| 02/14/2007 | EP1750696A2 Resistance-repellent retroviral protease inhibitors |
| 02/14/2007 | EP1750695A1 Use of furan alkyls for preparing a drug for treating obesity and cosmetically treating overweight |
| 02/14/2007 | EP1750694A2 Metabolites of selective androgen receptor modulators and methods of use thereof |
| 02/14/2007 | EP1750693A1 Oculoselective drugs and prodrugs |
| 02/14/2007 | EP1750692A2 Method of tonic treatment with oxyphenbutazone derivatives |
| 02/14/2007 | EP1750691A2 Compounds for treatment of aids and other diseases |
| 02/14/2007 | EP1750690A1 Use of targeted oxidative therapeutic formulation in treatment of cancer |
| 02/14/2007 | EP1750689A1 Treating seizures using ice inhibitors |
| 02/14/2007 | EP1750688A1 Steroid intraocular implants having an extended sustained release for a period of greater than 2 months |
| 02/14/2007 | EP1750687A2 Indole and azaindole derivatives with antitumor action |
| 02/14/2007 | EP1750686A1 Treatment of apoptosis |
| 02/14/2007 | EP1750682A2 Nutritional formulations |
| 02/14/2007 | EP1750675A1 Stable oral pharmaceutical compositions of buprenorphine and derivatives |
| 02/14/2007 | EP1750670A1 Buccal, polar and non-polar sprays containing propofol |
| 02/14/2007 | EP1750669A1 Solid pharmaceutical form comprising an ltb4 antagonist |
| 02/14/2007 | EP1750665A1 Biodegradable intravitreal tyrosine kinase inhibitors implants |
| 02/14/2007 | EP1750664A1 Intravitreal implants in conjunction with photodynamic therapy to improve vision |
| 02/14/2007 | EP1750655A1 Personal care compositions and methods for regulating mammalian hair growth and skin condition |
| 02/14/2007 | EP1750653A1 Use of heat shock protein inhibitorsfor the reduction of hair growth |
| 02/14/2007 | EP1750651A1 Composition for improving skin, hair and coat health containing flavanones |
| 02/14/2007 | EP1750525A2 Physiological cooling compositions |
| 02/14/2007 | EP1750523A1 Compositions and methods for reducing or preventing obesity |
| 02/14/2007 | EP1750522A1 Pet food compositions and methods |
| 02/14/2007 | EP1750509A2 Uridine effects on dopamine release |
| 02/14/2007 | EP1680128B1 Myo-inositol hexaphosphate for topical use |
| 02/14/2007 | EP1670782B1 Quinazoline derivatives |
| 02/14/2007 | EP1668005B1 Acyloxymethylcarbamate prodrugs of oxazolidinones |
| 02/14/2007 | EP1651640B1 Nicotinamide derivatives useful as pde4 inhibitors |